Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 735

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 735
---
 2,256,211 | ​ | ​ |
| Equity awards subject to outstanding Cara RSUs that fully vest uponconsummation of the Merger﻿(1)                                                         | ​ | ​ | ​                  | ​ |     40,330 | ​ | ​ | ​ | ​                 | ​ |     40,330 | ​ | ​ |
| Pro forma combined weighted average number of common stock outstanding                                                                                    | ​ | ​ | ​                  | ​ | 14,197,663 | ​ | ​ | ​ | ​                 | ​ | 14,161,956 | ​ | ​ |
| ​                                                                                                                                                         |   |   |                    |   |            |   |   |   |                   |   |            |   |   |

(1) Represents the total Cara RSUs expected to be included in common stock outstanding as of the Closing, after giving effect to the proposed Reverse Stock Split at an assumed ratio of 1-for-2, which includes 738 RSUs that vested subsequent to September 30, 2024 and 39,592 unvested RSUs outstanding as of the date of this proxy statement/prospectus, which will become vested in full upon the Closing.

429

TABLE OF CONTENTS

INDEX TO FINANCIAL STATEMENTS CARA THERAPEUTICS, INC.

| ​                                                                                                                         
 Financial Statements (Unaudited):                                                                                         
 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023                                      
 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023   | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | Page 
 ​    
 ​    
 ​    | ​ 
 ​ 
 ​ | ​   
 F-2 
 F-3 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ |
|:--------------------------------------------------------------------------------------------------------------------------|:--|:--|:-----|:--|:----|:--|:--|
| Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023 | ​ | ​ | ​    | ​ | F-4 | ​ | ​ |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023                     | ​ | ​ | ​    | ​ | F-6 | ​ | ​ |